Table 2.
The antibiotic susceptibility testing results of 100 K. pneumoniae isolates based on CLSI 2015.
| Antibiotic | Total K. pneumoniae No. (%) |
ESBL-producing K. pneumoniae No. (%) |
||||
|---|---|---|---|---|---|---|
| Resistant | Intermediate | Sensitive | Resistant | Intermediate | Sensitive | |
| Nitrofurantoin | 75 (75%) | 5 (5%) | 20 (20%) | 38 (76%) | 2 (4%) | 10 (20%) |
| Nalidixic acid | 55 (55%) | 5 (5%) | 40 (40%) | 25 (50%) | 2 (4%) | 23 (46%) |
| Cefepime | 50 (50%) | 5 (5%) | 45 (45%) | 29 (58%) | 1 (2%) | 20 (40%) |
| Gentamicin | 30 (30%) | 10 (10%) | 60 (60%) | 11 (22%) | 3 (6%) | 36 (72%) |
| Ceftazidime | 55 (55%) | 5 (5%) | 40 (40%) | 37 (74%) | 3 (6%) | 10 (20%) |
| Cefotaxime | 40 (40%) | 15 (15%) | 45 (45%) | 33 (66%) | 8 (16%) | 9 (18%) |
| Ciprofloxacin | 60 (60%) | 10 (10%) | 30 (30%) | 35 (70%) | 4 (8%) | 11 (22%) |
| Cefteriaxon | 40 (40%) | 15 (15%) | 45 (45%) | 32 (64%) | 8 (16%) | 10 (20%) |
| Trimethoprim/Sulfamethoxazole | 65 (65%) | 5 (5%) | 30 (30%) | 39 (78%) | 0 (0%) | 11 (22%) |
| Norfloxacin | 65 (65%) | 10 (10%) | 25 (25%) | 31 (62%) | 4 (8%) | 15 (30%) |
| Imipenem | 15 (15%) | 5 (5%) | 80 (80%) | 8 (16%) | 0 (0%) | 42 (84%) |
| Amikacin | 50 (50%) | 10 (10%) | 40 (40%) | 29 (58%) | 6 (12%) | 15 (30%) |